Table 4 Incremental cost-effectiveness ratio of 5 medicines from NLEM compare with budget and QALYs loss
Medicines (of the 43 medicines that had economic evaluation) | Indication | ICER | Budget (THB/year) | QALYs gained (A) | QALYs gained at WTP (B) | QALYs lost (A-B) |
|---|---|---|---|---|---|---|
Leuprorelin | Prostate cancer with intermediate risk | 137,613 | 351,000,000 | 2551 | 2194 | 357 |
Sorafenib | Metastatic clear cell renal cell carcinoma | 1,650,000 | 18,576,000 | 11 | 116 | − 105 |
Bortezomib | Multiple myeloma | 9,908,461 | 119,200,000 | 12 | 745 | − 733 |
Thalidomide | Multiple myeloma | 10,706,411 | 94,400,000 | 9 | 590 | − 581 |
Lenalidomide | Multiple myeloma | 12,009,328 | 167,200,000 | 14 | 1045 | − 1031 |